Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-274-4000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$301.03 million
Profitability
Miscellaneous
Employees499
Next Earnings Date10/23/2019 (Estimated)
OptionableOptionable
Sarepta Therapeutics (NASDAQ:SRPT) Frequently Asked Questions
What is Sarepta Therapeutics' stock symbol?
Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."
How were Sarepta Therapeutics' earnings last quarter?
Sarepta Therapeutics Inc (NASDAQ:SRPT) announced its quarterly earnings results on Wednesday, August, 7th. The biotechnology company reported ($3.74) earnings per share for the quarter, missing analysts' consensus estimates of ($1.08) by $2.66. The biotechnology company earned $94.67 million during the quarter, compared to analysts' expectations of $91.05 million. Sarepta Therapeutics had a negative net margin of 165.52% and a negative return on equity of 55.37%. Sarepta Therapeutics's revenue was up 28.8% on a year-over-year basis. During the same period last year, the firm earned ($1.67) earnings per share. View Sarepta Therapeutics' Earnings History.
When is Sarepta Therapeutics' next earnings date?
What price target have analysts set for SRPT?
20 brokers have issued 12-month target prices for Sarepta Therapeutics' stock. Their forecasts range from $6.00 to $267.00. On average, they anticipate Sarepta Therapeutics' share price to reach $192.00 in the next twelve months. This suggests a possible upside of 88.1% from the stock's current price. View Analyst Price Targets for Sarepta Therapeutics.
What is the consensus analysts' recommendation for Sarepta Therapeutics?
20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last year. There are currently 20 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sarepta Therapeutics.
What are Wall Street analysts saying about Sarepta Therapeutics stock?
Here are some recent quotes from research analysts about Sarepta Therapeutics stock:
- 1. Evercore ISI analysts commented, "We intend in connection with our next trial or set of trials associated with commercial material to address those issues and won’t move some of the restrictions that out of an overabundance or an abundance of caution exists within the protocol for what we call [indiscernible] (55:07) and now Study 102. So that our ultimate goal is to have the broadest possible coverage both of patients, age groups, geography but also genotype as well." (8/8/2019)
- 2. According to Zacks Investment Research, "Sarepta's Exondys 51 has witnessed impressive growth in 2018. Sarepta is also focused on reimbursement programs for better accessibility of the drug. Moreover, a potential approval to golodirsen will boost the company’s prospect as it will increase eligible patient population. Sarepta’s continues to progress with its DMD pipeline. The company is collaborating with companies and academic institutions to boost its DMD pipeline. However, dependence on a single product, Exondys 51, remains a concern. Meanwhile in December 2018, the company received a setback as it failed to gain approval for Exondys 51 in the EU. The DMD market is getting competitive as several other companies are developing therapies. The company’s shares have underperformed the industry so far this year. Loss estimates have narrowed ahead of the company’s Q1 earnings release. The company has a mixed record of earnings surprises in the recent quarters." (5/8/2019)
- 3. Cantor Fitzgerald analysts commented, ": Reiterate our Overweight rating and 12-mo. PT of $217. From our conversations with investors, we believe that awareness on limb girdle is increasing, but it remains low. We are publishing our 35-page prep pack discussing the disease, data expectations and potential stock moves. Sarepta will disclose 60- day biopsy data for MYO-101 in LGMD2E patients on Wed. morning (2/27). This is the first of five limb girdle readouts in the pipeline, which we think could drive significant upside to current valuation and diversify Sarepta beyond DMD. Sarepta remains a top pick." (2/22/2019)
- 4. HC Wainwright analysts commented, "Our $267 price target is derived from a risk-adjusted (does not include CMT or Sanfilippo A) DCF analysis and is based on: beta of 1.42, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 7.4%, and tax rate of 15% beginning in FY 2024." (1/4/2019)
Has Sarepta Therapeutics been receiving favorable news coverage?
Headlines about SRPT stock have trended positive on Tuesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Sarepta Therapeutics earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the immediate future. View News Stories for Sarepta Therapeutics.
Who are some of Sarepta Therapeutics' key competitors?
Some companies that are related to Sarepta Therapeutics include Shiseido (SSDOY), Takeda Pharmaceutical (TKPYY), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TAK), Alexion Pharmaceuticals (ALXN), GRIFOLS S A/S (GRFS), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Merck KGaA (MKGAF), Genmab A/S (GNMSF), Array Biopharma (ARRY), Ionis Pharmaceuticals (IONS), Mylan (MYL), Ono Pharmaceutical (OPHLF) and Alnylam Pharmaceuticals (ALNY).
What other stocks do shareholders of Sarepta Therapeutics own?
Who are Sarepta Therapeutics' key executives?
Sarepta Therapeutics' management team includes the folowing people:
- Mr. Douglas S. Ingram, Pres, CEO & Director (Age 56)
- Mr. Sandesh Mahatme LL.M., Exec. VP, CFO & Chief Bus. Officer (Age 54)
- Mr. David Tyronne Howton Jr., Exec. VP, Gen. Counsel & Corp. Sec. (Age 47)
- Mr. Alexander Bo Cumbo, Exec. VP & Chief Commercial Officer (Age 48)
- Dr. Edward M. Kaye, Advisor (Age 70)
Who are Sarepta Therapeutics' major shareholders?
Sarepta Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.38%), Price T Rowe Associates Inc. MD (5.25%), Janus Henderson Group PLC (3.68%), Janus Henderson Group PLC (3.68%), TimesSquare Capital Management LLC (1.69%) and Waddell & Reed Financial Inc. (1.42%). Company insiders that own Sarepta Therapeutics stock include Alexander Cumbo, David T Howton, Douglas S Ingram, Hans Lennart Rudolf Wigzell, Richard Barry, Sandesh Mahatme and Shamim Ruff. View Institutional Ownership Trends for Sarepta Therapeutics.
Which major investors are selling Sarepta Therapeutics stock?
SRPT stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Eagle Asset Management Inc., Farallon Capital Management LLC, Columbus Circle Investors, Senator Investment Group LP, Pinnacle Associates Ltd., Carillon Tower Advisers Inc. and Cormorant Asset Management LP. Company insiders that have sold Sarepta Therapeutics company stock in the last year include David T Howton, Hans Lennart Rudolf Wigzell and Sandesh Mahatme. View Insider Buying and Selling for Sarepta Therapeutics.
Which major investors are buying Sarepta Therapeutics stock?
SRPT stock was purchased by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Price T Rowe Associates Inc. MD, Nuveen Asset Management LLC, Vanguard Group Inc., Bessemer Group Inc., Pictet Asset Management Ltd., TimesSquare Capital Management LLC and Renaissance Technologies LLC. Company insiders that have bought Sarepta Therapeutics stock in the last two years include Douglas S Ingram and Richard Barry. View Insider Buying and Selling for Sarepta Therapeutics.
How do I buy shares of Sarepta Therapeutics?
Shares of SRPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sarepta Therapeutics' stock price today?
One share of SRPT stock can currently be purchased for approximately $102.07.
How big of a company is Sarepta Therapeutics?
Sarepta Therapeutics has a market capitalization of $7.59 billion and generates $301.03 million in revenue each year. The biotechnology company earns $-361,920,000.00 in net income (profit) each year or ($5.46) on an earnings per share basis. Sarepta Therapeutics employs 499 workers across the globe.View Additional Information About Sarepta Therapeutics.
What is Sarepta Therapeutics' official website?
How can I contact Sarepta Therapeutics?
Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-274-4000 or via email at [email protected]
MarketBeat Community Rating for Sarepta Therapeutics (NASDAQ SRPT)
MarketBeat's community ratings are surveys of what our community members think about Sarepta Therapeutics and other stocks. Vote "Outperform" if you believe SRPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
